about
The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.Semisynthesis and screening of a small library of pro-apoptotic squamocin analogues: selection and study of a benzoquinone hybrid with an improved biological profile.Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphomaCaspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton.Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphomaActivity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphomaTargeting the ubiquitin proteasome system: beyond proteasome inhibition.The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1.The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.Expression of dengue ApoptoM sequence results in disruption of mitochondrial potential and caspase activation.Ectopic expression of cyclin D1 impairs the proliferation and enhances the apoptosis of a murine lymphoid cell line.Drp1 mediates caspase-independent type III cell death in normal and leukemic cellsIn vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications.BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia.Dysfunction of the Fas apoptotic signaling pathway in persistent polyclonal B-cell lymphocytosis.Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release.The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.Caspase-independent type III PCD: a new means to modulate cell death in chronic lymphocytic leukemia.
P50
Q27852536-0436D441-1127-4DA1-B12B-C4E5D463C5D2Q30383411-12D333F3-F28B-42BB-9E82-509375D95A54Q30395557-6E2E8A8B-D1E9-42FD-BA04-6A95D662FC26Q30851212-12E9A161-D48C-42C5-BADF-2D18276A2B26Q33253057-321535CC-99D6-48E6-9A24-2D779FA818E3Q34414702-D85C4477-A50F-4EB9-ACBE-28A44E252A87Q34599670-A05CF636-BE02-4048-AF80-67B2B95A921CQ35475256-C2430F02-46CB-4EC8-8855-EADE5777B0ABQ37146042-227BC308-63CF-467F-B43A-98B12C080CA2Q37318226-A652D985-AC69-43C0-AF0A-125B64FE2038Q37718466-2641618B-6FEE-49E9-9814-DFB9E3F2E9F6Q37731677-6431F632-AA90-4A82-8A8C-6A99B334E740Q38062573-0473E1A4-A119-44A3-8179-F33F4D3E5531Q38656507-FBB55C19-2F4E-450F-A108-FC8BA181A31BQ38712214-4DDD7858-D0E6-492E-AF4E-78FBCBE580A8Q38726339-05B37DBA-16FD-4A41-8B95-EA42DE51B96DQ38745915-A1813C3A-43D8-4936-B5E5-1B3D74075097Q38847702-5722EB8E-C1D8-4DFE-9C6D-7A47FF47734BQ38957093-CF24105C-D555-4522-B6C3-2225FBC52D58Q38998097-DD03D40C-C22D-41C8-81ED-97C18BF9A8CDQ39068057-43348536-34E1-4590-A9BA-B0C6FECEA93DQ39210058-521266CF-CC90-4953-BC48-13B83BFA94B8Q39227871-8C53C28D-C2C5-498F-9F87-0D354C9B9670Q39299933-233C1650-3990-4C6E-9A48-966C1D60332CQ39528900-B1A2A2B9-89D5-4198-B005-781A2F16F142Q40547366-224C8FC1-7F4C-4BA9-A4C1-F209F593C021Q40811164-F36530C9-0CF4-4AEB-8C09-385C43100254Q42059338-14910B37-DAD0-4B19-B5C5-2E0A955E288DQ42222507-B5FA06F4-3BB5-4834-A888-752A00EC2D38Q42438129-43ECFB7A-E0AE-471A-9C07-2D6B9F785226Q42638579-222EA80D-299C-4B21-ABFF-B898AAA13266Q42705821-6A069C7C-0241-4479-BBAF-2130C7BA4288Q42924738-51C6BDE8-9C27-4822-BA51-052C73C73828Q43127276-0F944CB5-B18E-4DC0-94E1-A488AC4E9E64Q43764393-140302A7-B5A6-418F-A4A8-E935589028CFQ44327167-668E5A51-EC49-4AE3-B4B9-871F31D93D3AQ44636686-F4059175-62A4-4CAF-9572-CE5FC26C9C9DQ45594007-0D42B7F3-0622-44A9-AB22-D5115E3ECF77Q46058206-0651F8F5-22B7-4BAB-BE93-84BB676ACF17Q46249998-A9C33BA8-080F-4F50-8732-6408D059685D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gaël Roué
@ast
Gaël Roué
@en
Gaël Roué
@es
Gaël Roué
@nl
Gaël Roué
@sl
type
label
Gaël Roué
@ast
Gaël Roué
@en
Gaël Roué
@es
Gaël Roué
@nl
Gaël Roué
@sl
prefLabel
Gaël Roué
@ast
Gaël Roué
@en
Gaël Roué
@es
Gaël Roué
@nl
Gaël Roué
@sl
P1053
D-4759-2014
P106
P21
P31
P3829
P496
0000-0003-0245-2257
P569
2000-01-01T00:00:00Z